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Different cell sources for bone tissue engi-
neering are reviewed. In particular, adult cell
source strategies have been based on the implan-
tation of unfractionated fresh bone marrow; puri-
fied, culture expanded mesenchymal stem cells,
differentiated osteoblasts, or cells that have been
modified genetically to express rhBMP. Several
limiting factors are mentioned for these strategies
such as low number of available cells or possible
immunological reaction of the host. Foetal bone
cells are presented as an alternative solution and a
review of actual treatments using these cells is pre-
sented. Finally, foetal cells used specifically for
bone tissue engineering are characterised and po-
tentially interesting therapeutic options are pro-
posed.
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Bone regeneration is based on the hypothesis
that healthy progenitor cells, either recruited or
delivered to an injured site, can ultimately regen-
erate lost or damaged tissue. Three-dimensional
bone grafts may enhance bone regeneration by
creating and maintaining a space that facilitates
progenitor cell migration, proliferation and differ-
entiation [1]. Several techniques have been devel-
oped to provide the surgeon with needed material
for bone grafts. Pieces of bone are collected either
from the patients undergoing surgery (autograft,
which is considered as the gold standard and re-
mains the most used therapy for bone repair) or
obtained from a tissue bank (allograft). However,
these techniques have some drawbacks such as
traumatic procedures, morbidity or increased op-
erating times for autografts and limited supply,
risks of contamination or high costs for allografts.
These limitations have led to new research aiming
to provide a bone graft engineered in the labora-
tory and available when needed by the surgeon.
The ultimate goal of this new treatment strategy is
the regeneration rather than just the repair of
skeletal tissue [2]. From a broad point of view, this
approach can be defined as “bone tissue engineer-
ing”.
As for any application in tissue engineering,
the cell origin and type are essential aspects in bone
tissue engineering. Technically, the cells used
should be relatively simple with respect to their
collection, culture, expansion and storage. Thera-
peutically, the cells used should have high bone
formation potential, no immunological-induced
reactions and no pro-inflammatory properties. In
the following, we will i) review the existing options
available for adult cell sources and their limitations
for bone tissue engineering applications, ii) evalu-
ate the potential of using foetal cells for general tis-
sue engineering applications, and iii) present re-
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Adult cell sources for bone tissue engineering applications
Cell sources for bone tissue engineering appli-
cations can be categorised with respect to their
state of differentiation. With this idea, four differ-
ent cell-based tissue engineering approaches have
been described for the regeneration of bone.
These strategies are based on the implantation of
(1) unfractionated fresh bone marrow, (2) purified,
culture expanded mesenchymal stem cells. (3) dif-
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ferentiated osteoblasts, or (4) cells that have been
modified genetically to express rhBMP [3]. Gen-
erally, the less differentiated cells will be more eas-
ily expanded in vitro due to their high prolifera-
tion rate, while the differentiated cells will be more
effective in vivo due to their higher production of
mineralised extracellular matrix. 
For each type of cells used, advantages and dis-
advantages can be found. The cells from unfrac-
tionated fresh bone marrow are relatively easy to
collect, but it will not be possible to use these cells
in allotransplantation as bone marrow contains T
lymphocytes that encounter and respond to host
antigens in virtually all tissues in the body, leading
to multi-system graft-versus-host syndrome [4].
Mesenchymal stem cells, isolated from bone mar-
row aspirate, adult peripheral blood, neonatal cord
blood or liver for example, could present advan-
tages from an immunological point of view [5].
However, as one of every 100,000 nucleated cells
derived from bone marrow is a stem cell, a proce-
dure of isolation is required in order to decrease
the volume of material injected [6]. Compared to
unfractionated bone marrow, mesenchymal stem
cells have been shown to generate greater bone
formation in preclinical studies [7, 8]. However,
gradual loss of both their proliferative and differ-
entiation potential has been observed during in
vitro expansion [9]. To overcome this difficulty,
telomerase therapy (hTERT) has been recently
used and effectively extended stem cell life-span
while maintaining or even enhancing their os-
teogenic potential [10, 11]. Alternative sources of
autologous precursor cells were investigated in fat
by liposuction [12] or in skeletal muscle by biopsy
[13]. It has to be mentioned that pluripotential
cells from mesodermal tissues other than bone
marrow did not show bone healing in animal mod-
els [14].
The use of predifferentiated osteoblasts has
been shown to enhance the rate and extent of bone
regeneration [3, 15]. Their expansion in vitro may
be however difficult and is highly depending on the
donor [16]. Finally, cells genetically modified to
express bone formation cytokines could be used to
take advantage of genetic therapy, combining gene
therapy and tissue engineering methodologies to
enhance tissue regeneration [17]. The transfection
of the cells can be done either in two steps with an
in vitro transfection followed by injection of the
modified cells (procedure called ex vivo gene ther-
apy) or in one step by transfecting directly the cells
in the body (procedure called in vivo gene ther-
apy). With ex vivo gene therapy approach, cells
overexpressing BMP have been developed and
used in animal studies eg [18]. Concerns on possi-
ble host immune reaction need to be clarified.
A list of requirements for ideal cell sources 
for bone tissue engineering applications is sum-
marised in table 1. No adult cells seem to fulfil all
the requirements leaving room to propose an al-
ternative approach based on foetal cells.
Foetal cell sources for tissue engineering applications
Foetal associated tissues such as placenta, am-
niotic liquid or umbilical cord are described to be
potential sources of cells for tissue engineering
[19–22]. In contrast to embryonic tissue derived up
to the end of the 8th week, foetal tissue begins at
the 9th week and is considered as an organ dona-
tion. 
The idea of using foetal tissues or cells for cell
therapy is mainly coming from the field of neurol-
ogy. Indeed, several clinical studies have already
been performed to treat neurodegenerative disor-
ders. Neuronal affections such as Huntington’s
[23] or Parkinson’s disease [24] have been treated
by transplantation of fresh foetal neuroblasts. Un-
fortunately, these cells are difficult to expand in
culture and have to be transplanted freshly there-
fore needing large quantities of fresh tissue [25].
Still within the neurology but following accidents,
cell therapy for stroke has also tried to benefit from
foetal cells, with a clinical trial treating patients
with foetal cells obtained from the porcine primor-
dial striatum [26]. In this situation, safety of the
Technical requirements Therapeutical requirements
Collection Culture Expansion Storage Bone No-immuno- No pro-
formation logical inflammatory 
reaction reaction
Bone Marrow cells ++ NA NA NA + NA ++
Mesenchymal stem cells + ++ ++ ++ ++ ++ ++
Pre-osteoblasts + ++ + + ++ NA ++
Genetically modified cells1 ++ +2 ++ + +++ +3 ++
Foetal bone cells ++ +++ +++ +++ +++ +++ +++4
1 Ex vivo gene therapy
2 Effectiveness stability of the transfection may be difficult to obtain. Thus, the duration of the transfect expression could be affected.
3 Depending on the vectors used even for autologous transplantation [30] 
4 Foetal cells not only induce no pro-inflammatory reaction, but were able to decrease inflammation at the wounded site [29].
Table 1
List of requirements
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treatment was verified, but none of the patients
showed improvement. Treatment of spinal cord
injury also tested the use of intraspinal foetal cen-
tral nervous system grafts. Three clinical studies
have been performed where the results mainly
focused on security of the procedure. However,
encouraging results were obtained. In particular
translational correspondence was observed be-
tween preclinical locomotor performance in a cat
before and after intraspinal foetal transplant sur-
gery compared with a human subject before and
after human foetal cell grafting [27]. Transplanta-
tion of foetal central nervous system tissue is con-
sidered actually as a gold standard in neurobiology.
Beside neurology, human foetal liver cells have
been used already more than 10 years for trans-
plantation to treat severe immunodeficiencies,
haematological disorders and inborn errors of me-
tabolism when there was no perfectly matched
donor for marrow transplantation [28].
Recently, human foetal skin cells derived from
one cell bank (1–4 cm2 tissue results in over 10.5
million foetal skin constructs) were used in clini-
cal trials and new advances in tissue therapy are
possible with cellular constructs obtained from ex
vivo cultures [29]. Following this approach, engi-
neered regeneration of human skeletal adult tis-
sues could be also developed using human foetal
bone cells. Surprisingly, tissue engineering using
foetal cells has barely begun to be investigated. To
evaluate their potential integration in a bone engi-
neering strategy and following the experience
gained in neurobiology, a biological characterisa-
tion of these cells is necessary, especially by evalu-
ating the potential of foetal cells to produce min-
eralised bone extracellular matrix.
Lately, a study was performed to specifically
study the characteristics of human primary foetal
bone cells for a better comprehension of their bi-
ology in vitro and to evaluate their potential use
for tissue engineering in comparison to adult bone
cells and mesenchymal stem cells [16]. A summary
of this study is presented below.
In vitro evaluation of human foetal cells for bone tissue 
engineering applications
Human primary foetal bone cells were com-
pared to adult bone cells and mesenchymal stem
cells for their ability to proliferate and to differen-
tiate into osteoblasts in vitro (for details see the
original article [16]). Cell proliferation, gene ex-
pression of bone markers, alkaline phosphatase
(ALP) activity and mineralisation were analysed
during a time-course study. Human primary foetal
bone cells were compared to osteoblasts and mes-
enchymal stem cells obtained from adult tissues for
their ability to proliferate and to differentiate into
osteoblasts in vitro.
The doubling time of foetal bone cells was
comparable to mesenchymal stem cells but signif-
icantly shorter than for adult osteoblasts. Gene ex-
pression of cbfa-1, ALP, a1 chain of type I collagen
and osteocalcin were upregulated in foetal bone
cells after 12 days of treatment with osteogenic
factors, showing higher inductions than for adult
osteoblasts and mesenchymal stem cells. The in-
crease of ALP enzymatic activity was stronger for
foetal than for adult osteoblasts reaching a maxi-
mum at day 10, but lower than for mesenchymal
stem cells. Importantly, the mineralisation process
of bone foetal cells started earlier than adult os-
teoblasts and mesenchymal stem cells. The human
primary foetal bone cells have the advantages of
high proliferation rate as for mesenchymal stem
cells and effective production of mineralised extra-
cellular bone matrix as for adult osteoblasts. As
seen in table 1, human primary foetal bone cells
represent an interesting and promising potential
for therapeutic use in the bone tissue engineering
field as these cells can be easily stocked “frozen for
use” when necessary.
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